HLA-Cw6-positive and HLA-Cw6-negative patients with Psoriasis vulgaris have distinct clinical features.
about
Genetic epidemiology of psoriasis and psoriatic arthritisCollecting a set of psoriasis family material through a patient organisation; clinical characterisation and presence of additional disorders.Nail Psoriasis: A Review of Treatment OptionsThe role of natural killer cells in pathogenesis of autoimmune diseasesAllelic distribution of HLA class I genes in the Tibetan ethnic population of ChinaInteractions of the Immune System with Skin and Bone Tissue in Psoriatic Arthritis: A Comprehensive Review.Spondyloarthritis: Matrix Metalloproteinasesas Biomarkers of Pathogenesis and Response to Tumor Necrosis Factor (TNF) Inhibitors.A genetic risk score combining ten psoriasis risk loci improves disease prediction.Self-association of an activating natural killer cell receptor, KIR2DS1Comparison of MHC class I risk haplotypes in Thai and Caucasian psoriatics shows locus heterogeneity at PSORS1[Heinrich Köbner and the "isomorphic phenomenon". History and review of the literature].Genetic Epidemiology of PsoriasisCalcipotriene/betamethasone in the treatment of psoriasis: a review article.Hla-a and hla-B alleles associated in psoriasis patients from mumbai, Western IndiaImmunopathogenic mechanisms in psoriasis.TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis.HLA-Cw6 and HLA-DRB1*07 together are associated with less severe joint disease in psoriatic arthritis.Psoriasis and psoriatic arthritis: separate or one and the same?A susceptibility gene for psoriatic arthritis maps to chromosome 16q: evidence for imprinting.The role of 39 psoriasis risk variants on age of psoriasis onset.Activating killer cell Ig-like receptors in health and disease.Smoking and pathogenesis of psoriasis: a review of oxidative, inflammatory and genetic mechanisms.Predictors for clinical outcome in psoriatic arthritis - what have we learned from cohort studies?ERAP1 in the pathogenesis of ankylosing spondylitis.Increased Risk of Psoriasis due to combined effect of HLA-Cw6 and LCE3 risk alleles in Indian population.Association of IL12B risk haplotype and lack of interaction with HLA-Cw6 among the psoriasis patients in India.HLA-Cw6 homozygosity in plaque psoriasis is associated with streptococcal throat infections and pronounced improvement after tonsillectomy: A prospective case series.Early- and late-onset psoriasis: a cross-sectional clinical and immunocytochemical investigation.Characterisation of psoriasis susceptibility locus 6 (PSORS6) in patients with early onset psoriasis and evidence for interaction with PSORS1.The HLA-C*06 allele as a possible genetic predisposing factor to psoriasis in South Indian Tamils.Calcipotriene/betamethasone dipropionate for the treatment of psoriasis vulgaris: an evidence-based reviewA new extended haplotype Cw*0602-B57-DRB1*0701-DQA1*0201-DQB1*0201 associated with psoriasis in the Croatian population.TNF-α antagonists and nail psoriasis: an open, 24-week, prospective cohort study in adult patients with psoriasis.The HLA-Cw*06 allele and -1149 G/T polymorphism of extrapituitary promoter of PRL gene as a possible common genetic predisposing factors to psoriasis vulgaris and psoriatic arthritis in Czech population.The functional MICA-129 polymorphism is associated with skin but not joint manifestations of psoriatic disease independently of HLA-B and HLA-C.Molecular Mechanisms and Management of a Cutaneous Inflammatory Disorder: Psoriasis.Autoimmunity and autoimmune co-morbidities in psoriasis.HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study.HLA-C*06:02-independent, gender-related association of PSORS1C3 and PSORS1C1/CDSN single-nucleotide polymorphisms with risk and severity of psoriasis.Role of Human Leukocyte Antigens (HLA) in Autoimmune Diseases.
P2860
Q24674949-99C8AB38-3BC6-4A36-9A3B-60AF32DF430AQ24816472-56085531-57F5-48B4-836B-7C86E659C9D2Q26753038-A3A84F18-9375-40A5-8A26-81A3FF26D3FCQ26767143-CA092F6B-543F-4B68-91DF-EFE83FBF2A2CQ28274957-EE47C580-8B55-4808-90E2-BA4E7E6D4042Q30251957-07F4090C-2108-4AD6-9B47-FF18EEFB6480Q33624763-B4D2620A-CF11-4351-B4C2-0BD4D612DCCAQ33894914-1E66305B-ABBC-4830-BD4F-96CEA70284ADQ34017545-655695FE-FFA4-41EB-A42F-C240EEA21F2EQ34268080-9796E42C-DFFD-4A17-B8AA-8C0D90229B71Q34532112-113FDB7B-D971-4079-AC19-72CE8F8ADCABQ34845927-07B05DE8-B768-433A-8C15-0D68B1C12674Q34996165-56329050-9CAD-4061-B831-0C12906A39B9Q35564603-24DB934D-07A8-445C-A838-BFE11B6A257DQ35608884-F63B6BB4-204F-4145-8183-5D95CB94E9A3Q35754087-D3F9BD38-5704-4681-BA71-D48DAF766435Q35953347-4DFB821A-137E-4E99-89CD-993DA84EE9DBQ36921661-BC0CC7A4-21FA-4F56-AD03-0C9A72D30199Q37205203-D5B893CF-4822-44A1-8510-67CAB049ABCDQ37224869-89084F9E-2169-49F3-AC5C-FA314F6897D4Q37725657-2CB8249A-7998-4C77-8233-2150DF7AA3D6Q37903373-6DA95D70-89E8-478E-AADD-7AE1C19AECAAQ38202212-F455EF03-E93D-4E00-8446-F1713A8D8D38Q38272783-BE9EE5DE-6038-43F8-B4D7-3B5A82A80430Q38938170-7A6EC581-8C48-4BFB-A405-772A3A46BAEDQ39200679-517A77B3-5699-49FC-98BA-791EB3C97396Q39494092-A796F73A-8898-4A95-8F35-940A292AF520Q40510611-6E5E99E7-4D6E-4C80-8769-83986815A815Q40862474-D1ECA4F1-6E69-45C6-9FB2-BE1327BC3F88Q40959225-A86DF9D1-93EF-490B-92E7-B8CB67AB930AQ42370586-D4953D55-4C3F-42F7-854B-D89731F234D0Q43628532-2AE432D2-5BEB-464C-919F-F5B8CA8003FAQ44019438-3727DB48-EA7A-4462-9115-2CA134E4E720Q44381003-BE70B5A6-DBAD-4067-AEF1-E14C6E0F41DFQ44952683-B4319B06-BC3C-4B69-844D-5368AEF6BDEAQ48132042-E4685670-1148-4B00-8A97-825845EF86BDQ48283379-B4B3EB79-B0DB-4BBC-9BAE-C2C6D3006CC9Q50927361-D2E75440-F6D7-4540-86AE-66B27164F21BQ52339737-AE3DD790-F214-49FB-A5A3-60510CB51C1EQ52727983-4C69D48F-373E-4AA5-A626-73D96A6CF39E
P2860
HLA-Cw6-positive and HLA-Cw6-negative patients with Psoriasis vulgaris have distinct clinical features.
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
HLA-Cw6-positive and HLA-Cw6-n ...... ve distinct clinical features.
@ast
HLA-Cw6-positive and HLA-Cw6-n ...... ve distinct clinical features.
@en
HLA-Cw6-positive and HLA-Cw6-n ...... ve distinct clinical features.
@nl
type
label
HLA-Cw6-positive and HLA-Cw6-n ...... ve distinct clinical features.
@ast
HLA-Cw6-positive and HLA-Cw6-n ...... ve distinct clinical features.
@en
HLA-Cw6-positive and HLA-Cw6-n ...... ve distinct clinical features.
@nl
prefLabel
HLA-Cw6-positive and HLA-Cw6-n ...... ve distinct clinical features.
@ast
HLA-Cw6-positive and HLA-Cw6-n ...... ve distinct clinical features.
@en
HLA-Cw6-positive and HLA-Cw6-n ...... ve distinct clinical features.
@nl
P2093
P1476
HLA-Cw6-positive and HLA-Cw6-n ...... ve distinct clinical features.
@en
P2093
Ari Kárason
Arna A Antonsdóttir
E Hjaltey Rúnarsdóttir
Helgi Valdimarsson
Jeffrey R Gulcher
Jóhann E Gudjónsson
Kári Stefánsson
P304
P356
10.1046/J.0022-202X.2001.01656.X
P407
P577
2002-02-01T00:00:00Z
P5875
P6179
1048657000